 | • レポートコード：MRC23Q36250 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、89ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の腫瘍随伴性天疱瘡治療市場について調査・分析し、世界の腫瘍随伴性天疱瘡治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（皮下、静脈内、経口）、用途別セグメント分析（病院薬局、皮膚科クリニック、小売店薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Novartis Pharmaceuticals、Sanofi S.A.、Hoffmann-La-Roche、Pfizer Inc.、GlaxoSmithKline LLC、Teva Pharmaceuticals、Principia Biopharma, Inc.、Biogen, Inc.、Argenx、Teligent Inc.、Syntimmune、Almirallなどが含まれています。世界の腫瘍随伴性天疱瘡治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、腫瘍随伴性天疱瘡治療市場規模を推定する際に考慮しました。本レポートは、腫瘍随伴性天疱瘡治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、腫瘍随伴性天疱瘡治療に関するビジネス上の意思決定に役立てることを目的としています。 ・腫瘍随伴性天疱瘡治療市場の概要 - 腫瘍随伴性天疱瘡治療のタイプ別セグメント - 世界の腫瘍随伴性天疱瘡治療市場規模：タイプ別分析（皮下、静脈内、経口） - 腫瘍随伴性天疱瘡治療の用途別セグメント - 世界の腫瘍随伴性天疱瘡治療市場規模：用途別分析（病院薬局、皮膚科クリニック、小売店薬局、その他） - 世界の腫瘍随伴性天疱瘡治療市場規模予測（2018年-2029年） ・腫瘍随伴性天疱瘡治療市場の成長トレンド - 腫瘍随伴性天疱瘡治療の地域別市場規模（2018年-2029年） - 腫瘍随伴性天疱瘡治療市場ダイナミクス - 腫瘍随伴性天疱瘡治療の業界動向 - 腫瘍随伴性天疱瘡治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：皮下、静脈内、経口 - 世界の腫瘍随伴性天疱瘡治療のタイプ別市場規模（2018年-2023年） - 世界の腫瘍随伴性天疱瘡治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院薬局、皮膚科クリニック、小売店薬局、その他 - 世界の腫瘍随伴性天疱瘡治療の用途別市場規模（2018年-2023年） - 世界の腫瘍随伴性天疱瘡治療の用途別市場規模（2024年-2029年） ・腫瘍随伴性天疱瘡治療の地域別市場規模 - 北米の腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - アメリカの腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - ヨーロッパの腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - アジア太平洋の腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - 中国の腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - 日本の腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - 韓国の腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - インドの腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - オーストラリアの腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - 中南米の腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） - 中東・アフリカの腫瘍随伴性天疱瘡治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Novartis Pharmaceuticals、Sanofi S.A.、Hoffmann-La-Roche、Pfizer Inc.、GlaxoSmithKline LLC、Teva Pharmaceuticals、Principia Biopharma, Inc.、Biogen, Inc.、Argenx、Teligent Inc.、Syntimmune、Almirall ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Paraneoplastic Pemphigus Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Paraneoplastic Pemphigus Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Paraneoplastic Pemphigus Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Paraneoplastic Pemphigus Treatment in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Paraneoplastic Pemphigus Treatment include Novartis Pharmaceuticals, Sanofi S.A., Hoffmann-La-Roche, Pfizer Inc., GlaxoSmithKline LLC, Teva Pharmaceuticals, Principia Biopharma, Inc., Biogen, Inc. and Argenx, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Paraneoplastic Pemphigus Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Paraneoplastic Pemphigus Treatment.
The Paraneoplastic Pemphigus Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Paraneoplastic Pemphigus Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Paraneoplastic Pemphigus Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Novartis Pharmaceuticals
Sanofi S.A.
Hoffmann-La-Roche
Pfizer Inc.
GlaxoSmithKline LLC
Teva Pharmaceuticals
Principia Biopharma, Inc.
Biogen, Inc.
Argenx
Teligent Inc.
Syntimmune
Almirall
Segment by Type
Subcutaneous
Intravenous
Oral
Segment by Application
Hospital Pharmacies
Dermatology Clinics
Retail Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Paraneoplastic Pemphigus Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Paraneoplastic Pemphigus Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Subcutaneous
1.2.3 Intravenous
1.2.4 Oral
1.3 Market by Application
1.3.1 Global Paraneoplastic Pemphigus Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Dermatology Clinics
1.3.4 Retail Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Paraneoplastic Pemphigus Treatment Market Perspective (2018-2029)
2.2 Paraneoplastic Pemphigus Treatment Growth Trends by Region
2.2.1 Global Paraneoplastic Pemphigus Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Paraneoplastic Pemphigus Treatment Historic Market Size by Region (2018-2023)
2.2.3 Paraneoplastic Pemphigus Treatment Forecasted Market Size by Region (2024-2029)
2.3 Paraneoplastic Pemphigus Treatment Market Dynamics
2.3.1 Paraneoplastic Pemphigus Treatment Industry Trends
2.3.2 Paraneoplastic Pemphigus Treatment Market Drivers
2.3.3 Paraneoplastic Pemphigus Treatment Market Challenges
2.3.4 Paraneoplastic Pemphigus Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Paraneoplastic Pemphigus Treatment Players by Revenue
3.1.1 Global Top Paraneoplastic Pemphigus Treatment Players by Revenue (2018-2023)
3.1.2 Global Paraneoplastic Pemphigus Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Paraneoplastic Pemphigus Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Paraneoplastic Pemphigus Treatment Revenue
3.4 Global Paraneoplastic Pemphigus Treatment Market Concentration Ratio
3.4.1 Global Paraneoplastic Pemphigus Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Paraneoplastic Pemphigus Treatment Revenue in 2022
3.5 Paraneoplastic Pemphigus Treatment Key Players Head office and Area Served
3.6 Key Players Paraneoplastic Pemphigus Treatment Product Solution and Service
3.7 Date of Enter into Paraneoplastic Pemphigus Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Paraneoplastic Pemphigus Treatment Breakdown Data by Type
4.1 Global Paraneoplastic Pemphigus Treatment Historic Market Size by Type (2018-2023)
4.2 Global Paraneoplastic Pemphigus Treatment Forecasted Market Size by Type (2024-2029)
5 Paraneoplastic Pemphigus Treatment Breakdown Data by Application
5.1 Global Paraneoplastic Pemphigus Treatment Historic Market Size by Application (2018-2023)
5.2 Global Paraneoplastic Pemphigus Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Paraneoplastic Pemphigus Treatment Market Size (2018-2029)
6.2 North America Paraneoplastic Pemphigus Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Paraneoplastic Pemphigus Treatment Market Size by Country (2018-2023)
6.4 North America Paraneoplastic Pemphigus Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Paraneoplastic Pemphigus Treatment Market Size (2018-2029)
7.2 Europe Paraneoplastic Pemphigus Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Paraneoplastic Pemphigus Treatment Market Size by Country (2018-2023)
7.4 Europe Paraneoplastic Pemphigus Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Paraneoplastic Pemphigus Treatment Market Size (2018-2029)
8.2 Asia-Pacific Paraneoplastic Pemphigus Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Paraneoplastic Pemphigus Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Paraneoplastic Pemphigus Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Paraneoplastic Pemphigus Treatment Market Size (2018-2029)
9.2 Latin America Paraneoplastic Pemphigus Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Paraneoplastic Pemphigus Treatment Market Size by Country (2018-2023)
9.4 Latin America Paraneoplastic Pemphigus Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Paraneoplastic Pemphigus Treatment Market Size (2018-2029)
10.2 Middle East & Africa Paraneoplastic Pemphigus Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Paraneoplastic Pemphigus Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Paraneoplastic Pemphigus Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis Pharmaceuticals
11.1.1 Novartis Pharmaceuticals Company Detail
11.1.2 Novartis Pharmaceuticals Business Overview
11.1.3 Novartis Pharmaceuticals Paraneoplastic Pemphigus Treatment Introduction
11.1.4 Novartis Pharmaceuticals Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.1.5 Novartis Pharmaceuticals Recent Development
11.2 Sanofi S.A.
11.2.1 Sanofi S.A. Company Detail
11.2.2 Sanofi S.A. Business Overview
11.2.3 Sanofi S.A. Paraneoplastic Pemphigus Treatment Introduction
11.2.4 Sanofi S.A. Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.2.5 Sanofi S.A. Recent Development
11.3 Hoffmann-La-Roche
11.3.1 Hoffmann-La-Roche Company Detail
11.3.2 Hoffmann-La-Roche Business Overview
11.3.3 Hoffmann-La-Roche Paraneoplastic Pemphigus Treatment Introduction
11.3.4 Hoffmann-La-Roche Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.3.5 Hoffmann-La-Roche Recent Development
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Detail
11.4.2 Pfizer Inc. Business Overview
11.4.3 Pfizer Inc. Paraneoplastic Pemphigus Treatment Introduction
11.4.4 Pfizer Inc. Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.4.5 Pfizer Inc. Recent Development
11.5 GlaxoSmithKline LLC
11.5.1 GlaxoSmithKline LLC Company Detail
11.5.2 GlaxoSmithKline LLC Business Overview
11.5.3 GlaxoSmithKline LLC Paraneoplastic Pemphigus Treatment Introduction
11.5.4 GlaxoSmithKline LLC Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.5.5 GlaxoSmithKline LLC Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Detail
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Paraneoplastic Pemphigus Treatment Introduction
11.6.4 Teva Pharmaceuticals Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Principia Biopharma, Inc.
11.7.1 Principia Biopharma, Inc. Company Detail
11.7.2 Principia Biopharma, Inc. Business Overview
11.7.3 Principia Biopharma, Inc. Paraneoplastic Pemphigus Treatment Introduction
11.7.4 Principia Biopharma, Inc. Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.7.5 Principia Biopharma, Inc. Recent Development
11.8 Biogen, Inc.
11.8.1 Biogen, Inc. Company Detail
11.8.2 Biogen, Inc. Business Overview
11.8.3 Biogen, Inc. Paraneoplastic Pemphigus Treatment Introduction
11.8.4 Biogen, Inc. Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.8.5 Biogen, Inc. Recent Development
11.9 Argenx
11.9.1 Argenx Company Detail
11.9.2 Argenx Business Overview
11.9.3 Argenx Paraneoplastic Pemphigus Treatment Introduction
11.9.4 Argenx Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.9.5 Argenx Recent Development
11.10 Teligent Inc.
11.10.1 Teligent Inc. Company Detail
11.10.2 Teligent Inc. Business Overview
11.10.3 Teligent Inc. Paraneoplastic Pemphigus Treatment Introduction
11.10.4 Teligent Inc. Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.10.5 Teligent Inc. Recent Development
11.11 Syntimmune
11.11.1 Syntimmune Company Detail
11.11.2 Syntimmune Business Overview
11.11.3 Syntimmune Paraneoplastic Pemphigus Treatment Introduction
11.11.4 Syntimmune Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.11.5 Syntimmune Recent Development
11.12 Almirall
11.12.1 Almirall Company Detail
11.12.2 Almirall Business Overview
11.12.3 Almirall Paraneoplastic Pemphigus Treatment Introduction
11.12.4 Almirall Revenue in Paraneoplastic Pemphigus Treatment Business (2018-2023)
11.12.5 Almirall Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details